Why the study?
Does quercetin reduce cisplatin-induced acute tubular necrosis in a rat model?
Does quercetin reduce cisplatin-induced acute tubular necrosis in a rat model?
In a rat model, prophylactic administration of quercetin attenuated cisplatin-induced acute tubular necrosis and associated functional and histological changes.
Answers are grounded in this paper and cite their sources.
Supports further preclinical quercetin research for cisplatin nephroprotection; leaves open clinical translation and should not change practice.
BACKGROUND: The mechanism of cisplatin-induced nephrotoxicity is unknown, but has been associated with renal lipid peroxidation. The bioflavonoid quercetin may be a potential alternative to reduce cisplatin-induced nephrotoxicity. The aim of this study was to evaluate the effect of quercetin on the evolution of cisplatin-induced acute tubular necrosis. METHODS: One hundred and three male Wistar rats were injected with cisplatin (5 mg/kg, i.p.), 43 of them received quercetin (50 mg/kg, by gavage) before cisplatin injection. Blood and urine were collected 5 and 20 days after the injection for the determination of plasma creatinine, urine volume and osmolality. The kidneys were removed for the determination of renal malondialdehyde (MDA) and for histological and immunohistochemical studies. The renal expression of fibronectin, alpha-smooth muscle actin, vimentin, Jun N-terminal kinase, nuclear factor-kappaB, and macrophages during the evolution of the acute tubular necrosis induced by cisplatin and the histological changes observed in the kidneys were analyzed. RESULTS: Cisplatin-treated rats presented a transitory increase in plasma creatinine levels, tubular cell necrosis and increased immunostaining for vimentin, alpha-SM-actin, fibronectin, ED1, NF-kappaB, and p-JNK in the renal cortex and outer medulla. These alterations were less intense in animals treated with quercetin. CONCLUSION: Quercetin treatment attenuated the functional, histological and immunohistochemical alterations induced by cisplatin.
No takes yet. Share an insight, caveat, or question.
Francescato et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: